Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

METHYLTRANSFERASE DRUG DISCOVERY

Award Number: R43CA139621
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2009
PERIOD OF PERFORMANCE END DATE: 03/31/2010

Group Awards By:

View Award Description

METHYLTRANSFERASE DRUG DISCOVERY - DESCRIPTION (provided by applicant): Chromatin assembly and structure is highly regulated during DNA replication, gene expression, and progression through the cell cycle. Dysfunction of epigenetic factors, including methylation state, are associated with a variety of cancers. Histone lysine methyltransferases (HKMTs) are considered a new and important class of drug targets, however high throughput screening (HTS) assay formats are not available and reference inhibitors remain unknown. HTS assays and reference compounds would have significant potential to help elucidate function of these enzymes and to facilitate the development of anticancer agents. Reaction Biology Corporation (RBC) has developed extremely low cost reaction systems for many enzyme classes to serve markets for ultra high throughput screening (uHTS) drug discovery, large scale IC50 determinations and selectivity/toxicity profiling. The HotSpot platform employs a gold standard for ultralow volume radioisotope assays for kinase profiling. This service product for kinase profiling is widely accepted in the drug discovery community for kinase inhibitor development. Based on these skills, RBC seeks to develop a new assay platform using gold standard radioisotope assays for the large family of histone lysine methyltransferases (HKMTs). Through Phase I funding, the proposed research will focus on the following three aims: Aim 1 Develop a universal radioisotope-based gold standard for HKMTs with large signal/background ratio; Aim 2 Reduce assay costs by ultra-miniaturization and streamline assay protocols for robust HTS; Aim 3 Conduct HTS and identify new compounds for an HKMT using assays developed in Aims 1 and 2 by screening the libraries from RBC's chemical repository. This work will enable Phase II activities where RBC will expand its assay range across the large human HKMTs family and use this newly developed universal assay against large synthetic and natural compound libraries to discover potential molecules for research and therapeutic development. Selected lead compounds will be evaluated in cell based assays for anti-cancer activities PUBLIC HEALTH RELEVANCE: Chromatin assembly and structure is highly regulated during DNA replication, gene expression, and progression through the cell cycle. Dysfunction of epigenetic factors, including methylation state, are associated with a variety of cancers. Histone lysine methyltransferases are considered a new and important class of drug targets, however high throughput screening assay formats are not available and reference inhibitors remain unknown. HTS assays and reference compounds would have significant potential to help elucidate function of these enzymes and to facilitate the development of anticancer agents. Reaction Biology Corporation has developed extremely low cost reaction systems for many enzyme classes to serve markets for ultra high throughput screening drug discovery, large scale IC50 determinations and selectivity/toxicity profiling. The HotSpot platform employs a gold standard for ultralow volume radioisotope assays for kinase profiling. This service product for kinase profiling is widely accepted in the drug discovery community for kinase inhibitor development. Based on these skills, RBC seeks to develop a new assay platform using gold standard radioisotope assays for the large family of histone lysine methyltransferases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $170,727 )
2009	2009	REACTION BIOLOGY CORPORATION	1764 LITCHFIELD TURNPIKE, 203	WOODBRIDGE	CT	06525	SOUTH CENTRAL CT	USA	Cancer Cause and Prevention Research	000	1	4/13/2009	NEW	$170,727
														Subtotal = $170,727

Grand Total All Awards = $170,727

Top

All Categories

About

Search

Reports

Data Submission

Award Information

METHYLTRANSFERASE DRUG DISCOVERY

Award Number: R43CA139621

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2009

PERIOD OF PERFORMANCE END DATE: 03/31/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer